Straits Times Index
3,095.59 -6.62 (-0.21%) Nikkei
25,935.62 -457.42 (-1.73%) Hang Seng
21,859.79 -137.10 (-0.62%) FTSE 100
7,168.65 -0.63 (-0.01%) BTC-USD
19,295.26 -66.05 (-0.34%) CMC Crypto 200
420.84 +0.70 (+0.17%)
Swedish Orphan Biovitrum AB (publ) (B6E.F)
| Previous close | 20.33 |
| Open | 20.19 |
| Bid | 20.71 x 76000 |
| Ask | 21.01 x 74000 |
| Day's range | 19.93 - 20.45 |
| 52-week range | 15.10 - 24.26 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 6.11B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 25.44 |
| EPS (TTM) | 0.80 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
- Reuters
Drugmaker Sobi books profit fall on restructuring, Russia
Swedish Orphan Biovitrum (Sobi) on Thursday reported a smaller-than-expected first-quarter operating profit and said sales grew in emerging markets for its drug Kineret for the treatment of COVID-19. The rare disease drugmaker's operating profit fell to 776 million crowns ($78.6 million) from 1.03 billion and missed the 1.16 billion expected by analysts polled by Refinitiv. The group, which sells drugs targeted at haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, booked restructuring costs of 507 million and a 157 million provision for expected credit losses in Russia.
